Global Leader in Specialty Therapeutics Selects Kneat to Digitize Validation
Kneat.com (TSX: KSI, OTCQX: KSIOF) has secured a three-year Master Services Agreement with a major global therapeutics company to digitize its validation processes. The unnamed European company employs over 20,000 people across 100+ countries and operates more than ten manufacturing sites globally.
The client company provides supplies for Life Sciences organizations, focusing on research, clinical trials, manufacturing, diagnosis, and treatment. They will initially implement Kneat Gx for commissioning, qualification, and validation of manufacturing equipment and facilities. The partnership represents continued momentum for Kneat in attracting global Life Sciences leaders to its platform.
Kneat.com (TSX: KSI, OTCQX: KSIOF) ha ottenuto un Contratto Quadro di Servizi Triennale con una grande azienda globale nel settore delle terapie per digitalizzare i suoi processi di validazione. L'azienda europea, il cui nome non 猫 stato rivelato, impiega oltre 20.000 persone in pi霉 di 100 paesi e gestisce pi霉 di dieci centri di produzione in tutto il mondo.
L'azienda cliente fornisce forniture per le organizzazioni delle Scienze della Vita, concentrandosi su ricerca, sperimentazioni cliniche, produzione, diagnosi e trattamento. Inizialmente, implementeranno Kneat Gx per la messa in servizio, la qualificazione e la validazione delle attrezzature e delle strutture di produzione. Questa partnership rappresenta un ulteriore slancio per Kneat nell'attrarre i leader globali delle Scienze della Vita sulla sua piattaforma.
Kneat.com (TSX: KSI, OTCQX: KSIOF) ha asegurado un Contrato Marco de Servicios de Tres A帽os con una importante empresa global de terapias para digitalizar sus procesos de validaci贸n. La empresa europea, cuyo nombre no ha sido revelado, emplea a m谩s de 20,000 personas en m谩s de 100 pa铆ses y opera m谩s de diez sitios de manufactura a nivel mundial.
La empresa cliente proporciona suministros a organizaciones de Ciencias de la Vida, centr谩ndose en investigaci贸n, ensayos cl铆nicos, manufactura, diagn贸stico y tratamiento. Inicialmente, implementar谩n Kneat Gx para la puesta en marcha, calificaci贸n y validaci贸n de equipos e instalaciones de manufactura. Esta asociaci贸n representa un impulso continuo para Kneat en la atracci贸n de l铆deres globales en Ciencias de la Vida a su plataforma.
Kneat.com (TSX: KSI, OTCQX: KSIOF)電� 欤检殧 旮�搿滊矊 旃橂 須岇偓鞕� 3雲� 毵堨姢韯� 靹滊箘鞀� 瓿勳暯鞚� 觳搓舶頃橃棳 瓴�歃� 頂勲靹胳姢毳� 霐旍韯疙檾頃橁矊 霅╇媹雼�. 鞚措鞚� 瓿店皽霅橃 鞎婌潃 鞚� 鞙犽熃 須岇偓電� 100臧� 鞚挫儊鞚� 甑皜鞐愳劀 20,000氇� 鞚挫儊鞚� 歆侅洂鞚� 瓿犾毄頃橁碃 鞛堨溂氅�, 鞝� 靹戈硠鞐� 10臧� 鞚挫儊鞚� 鞝滌“ 鞁滌劋鞚� 鞖挫榿頃橁碃 鞛堨姷雼堧嫟.
韥措澕鞚挫柛韸� 須岇偓電� 靸濍獏 瓿柬暀 臁办鞐� 頃勳殧頃� 瓿店笁頀堨潉 鞝滉车頃橂┌, 鞐瓣惮, 鞛勳儊 鞁滍棙, 鞝滌“, 歆勲嫧 氚� 旃橂鞐� 歆戩頃橁碃 鞛堨姷雼堧嫟. 鞚措摛鞚� 觳橃潓鞐� Kneat Gx毳� 鞝滌“ 鞛ル箘 氚� 鞁滌劋鞚� 旎る靺旊嫕, 鞛愱博 攵�鞐� 氚� 瓴�歃濎潉 鞙勴暣 甑槃頃� 瓴冹瀰雼堧嫟. 鞚措矆 韺岉姼雱堨嫮鞚� Kneat鞚� 靸濍獏 瓿柬暀 攵勳暭鞚� 旮�搿滊矊 毽崝毳� 頂岆灚韽检棎 鞙犾箻頃橂姅 雿� 歆�靻嶌爜鞚� 氇韰�鞚� 臧�鞝胳槫瓿� 鞛堨姷雼堧嫟.
Kneat.com (TSX: KSI, OTCQX: KSIOF) a conclu un Contrat Cadre de Services de Trois Ans avec une grande entreprise mondiale de th茅rapies pour num茅riser ses processus de validation. L'entreprise europ茅enne, dont le nom n'est pas divulg茅, emploie plus de 20 000 personnes dans plus de 100 pays et exploite plus de dix sites de production 脿 l'茅chelle mondiale.
L'entreprise cliente fournit des fournitures aux organisations des sciences de la vie, en se concentrant sur la recherche, les essais cliniques, la fabrication, le diagnostic et le traitement. Dans un premier temps, ils mettront en 艙uvre Kneat Gx pour la mise en service, la qualification et la validation des 茅quipements et des installations de fabrication. Ce partenariat repr茅sente une dynamique continue pour Kneat dans l'attraction des leaders mondiaux des sciences de la vie vers sa plateforme.
Kneat.com (TSX: KSI, OTCQX: KSIOF) hat einen Dreijahres-Master-Service-Vertrag mit einem gro脽en globalen Therapeutikunternehmen abgeschlossen, um dessen Validierungsprozesse zu digitalisieren. Das nicht namentlich genannte europ盲ische Unternehmen besch盲ftigt 眉ber 20.000 Mitarbeiter in mehr als 100 L盲ndern und betreibt weltweit mehr als zehn Produktionsstandorte.
Das Kundenunternehmen liefert Materialien f眉r Organisationen im Bereich der Lebenswissenschaften und konzentriert sich auf Forschung, klinische Studien, Fertigung, Diagnostik und Behandlung. Zun盲chst wird Kneat Gx f眉r die Inbetriebnahme, Qualifizierung und Validierung von Fertigungsanlagen und -einrichtungen implementiert. Die Partnerschaft stellt eine fortlaufende Dynamik f眉r Kneat dar, um globale F眉hrungspers枚nlichkeiten der Lebenswissenschaften f眉r seine Plattform zu gewinnen.
- Secured new three-year Master Services Agreement with major global company
- Client has significant global presence (20,000+ employees, 100+ countries)
- Expansion into validation processes for multiple manufacturing sites
- None.
LIMERICK, Ireland, Jan. 09, 2025 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that a leading global therapeutics company (鈥渢he Company鈥�) has signed a three-year Master Services Agreement with Kneat to digitize its validation processes.
This European-headquartered Company employs more than 20,000 people and operates in over 100 countries, with more than ten globally dispersed manufacturing sites. The Company provides supplies for companies working throughout the Life Sciences, including in research, clinical trials, manufacturing, diagnosis, and treatment. It also develops, produces, and provides innovative healthcare services and solutions to diagnose and treat a range of diseases, including rare conditions, for millions of patients around the world.聽聽
With capabilities across the full value chain from R&D through to manufacturing and final distribution, the Company maintains a range of systems and processes requiring validation. They will use Kneat Gx initially for commissioning, qualification and validation of manufacturing equipment and facilities.
鈥淭his win continues our strong momentum attracting global Life Sciences leaders to our platform,鈥� said Eddie Ryan, Chief Executive Officer of Kneat. 鈥淲e look forward to supporting this company on their digitalization journey for all their validation processes.鈥�
About Kneat
Kneat Solutions provides leading companies in highly regulated industries with unparalleled efficiency in validation and compliance through its digital validation platform Kneat Gx. As an industry leader in customer satisfaction, Kneat boasts an excellent record for implementation, powered by our user-friendly design, expert support, and on-demand training academy. Kneat Gx is an industry-leading digital validation platform that enables highly regulated companies to manage any validation discipline from end-to-end. Kneat Gx is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Multiple independent customer studies report up to
Cautionary and Forward-Looking Statements
Except for the statements of historical fact contained herein, certain information presented constitutes 鈥渇orward-looking information鈥� within the meaning of applicable Canadian securities laws. Such forward-looking information includes, but is not limited to, the relationship between Kneat and the customer, Kneat鈥檚 business development activities, the use and implementation timelines of Kneat鈥檚 software within the customer鈥檚 validation processes, the ability and intent of the customer to scale the use of Kneat鈥檚 software within the customer鈥檚 organization, and the compliance of Kneat鈥檚 platform under regulatory audit and inspection. While such forward-looking statements are expressed by Kneat, as stated in this release, in good faith and believed by Kneat to have a reasonable basis, they are subject to important risks and uncertainties. As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events. These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties.
Kneat does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement. Continued reliance on forward-looking statements is at an investor鈥檚 own risk.
For further information:
Katie Keita, Kneat Investor Relations
P: + 1 902-450-2660
E:
FAQ
What is the duration of Kneat's new Master Services Agreement announced in January 2025?
How many manufacturing sites will implement Kneat's validation software?
What specific Kneat product will be implemented for validation processes?
What is the global presence of the therapeutics company partnering with KSIOF?
What areas will the new client use Kneat's software for initially?
